Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs
By
Joseph Haas / Email the Author / “The Pink Sheet” DAILY Dec. 12, 2011
Word Count: 1181 / Article # 14111212004
Executive Summary
Adding on to the two companies’ collaboration around chronic kidney disease candidate bardoxolone, Abbott will pay a record upfront for preclinical assets to co-develop and co-commercialize Reata’s antioxidant inflammation modulators in a variety of disease areas.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.